Biointron
Latest round
- Series B
Last raised
- Aug 2022
Total raised
- $88M
Investors
- 13
About Biointron
Based in Jiangsu, China and established in 2012, Biointron operates as a contract research organization (CRO) vendor that engages in recombinant antibody drug R&D and related outsourcing services. The company has R&D and production center located in Jiangsu and business center located in the USA and Netherlands. It has more than 400 employees and over 14,600 square meter production area. The company provides recombinant protein and antibody reagents for biotech and biopharma companies. The company develops high throughput recombinant antibody expression platform, phage library antibody development platform and single cell antibody development platform. It adopts microfluidic sorting and identification technologies. The business of the company includes antibody discovery, antibody production, stable cell line and protein expression. Antibody discovery include VHH library generation, single B cell screening, hybridoma sequencing, antibody humanization and affinity maturation.
Who invested in Biointron
13 investors across 3 rounds
See all investors in Biointron
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Biointron
Who invested in Biointron?
Biointron has 13 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Biointron raised?
Biointron has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Biointron last raise money?
Biointron's most recent round on record is a Series B, in Aug 2022.
What does Biointron do?
Based in Jiangsu, China and established in 2012, Biointron operates as a contract research organization (CRO) vendor that engages in recombinant antibody drug R&D and related outsourcing services.
Where is Biointron headquartered?
Biointron is headquartered in Shanghai, China.
Which VCs invest in companies like Biointron?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Biointron's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Biointron? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.